Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $56.00 USD
Change Today +0.41 / 0.74%
Volume 986.1K
CPHD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

cepheid inc (CPHD) Snapshot

Open
$55.70
Previous Close
$55.59
Day High
$56.13
Day Low
$54.66
52 Week High
07/20/15 - $63.69
52 Week Low
08/15/14 - $37.12
Market Cap
4.0B
Average Volume 10 Days
1.4M
EPS TTM
$-0.38
Shares Outstanding
71.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEPHEID INC (CPHD)

cepheid inc (CPHD) Related Businessweek News

No Related Businessweek News Found

cepheid inc (CPHD) Details

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual health, women’s health, virology, oncology, and genetics. It also provides SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample; and GeneXpert Infinity System for high volume testing. The company sells its products through its direct sales force and distributors worldwide. It has collaboration agreements with FIND to develop a test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples; Life Technologies Corporation to develop reagents for use in the USPS BDS program; AstraZeneca plc, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, and others to develop Xpert Carba-R, a rapid diagnostic test; and Paul G. Allen Family Foundation and the BMGF to develop Xpert Ebola, a rapid test that. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

1,400 Employees
Last Reported Date: 02/26/15
Founded in 1996

cepheid inc (CPHD) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $664.9K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $398.0K
President of Hbdc
Total Annual Compensation: $433.5K
Chief Regulatory Officer and Executive Vice P...
Total Annual Compensation: $352.5K
Executive Vice President of Worldwide Commerc...
Total Annual Compensation: $236.2K
Compensation as of Fiscal Year 2014.

cepheid inc (CPHD) Key Developments

Cepheid Announces International Availability of an Update to Xpert Carba-R

Cepheid announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48. The updated Xpert Carba-R is now shipping as a CE-IVD Mark product.

Cepheid Unveils the GeneXpert® Omni

Cepheid unveiled the GeneXpert® Omni, a flexible and portable clinical molecular diagnostic system designed to meet the needs of the Point of Care market. At just 9 inches tall, and weighing just 2.2 pounds, the GeneXpert Omni will run the same high quality PCR-based Xpert® cartridges as Cepheid's existing family of GeneXpert Systems, enabling highly accurate clinical molecular diagnostic tests to be performed in any near-patient testing environment, including CLIA-waived physician offices, clinics and specialty settings.

Cepheid Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter and Full Year Ending December 31, 2015; Provides Revenue Guidance for the Fourth Quarter of 2015

Cepheid announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's revenue was $132.5 million compared with $116.5 million a year ago. Loss from operations was $10.8 million compared with $5.6 million a year ago. Loss before income taxes was $15.5 million compared with $8.9 million a year ago. Net loss was $16.7 million or $0.23 per basic and diluted share compared with $9.8 million or $0.14 per basic and diluted share a year ago. Non-GAAP measure of loss from operations was $1.1 million compared with income of $4.2 million a year ago. Non-GAAP measure of net loss was $4.5 million or $0.06 per basic and diluted share compared with net income of $2.3 million or $0.03 per basic and diluted share a year ago. For the six months, the company's revenue was $265.1 million compared with $223.4 million a year ago. Loss from operations was $6.1 million compared with $11.9 million a year ago. Loss before income taxes was $15.0 million compared with $17.5 million a year ago. Net loss was $15.8 million or $0.22 per basic and diluted share compared with $19.1 million or $0.27 per basic and diluted share a year ago. Net cash provided by operating activities was $7.9 million compared with net cash used in operating activities of $8.6 million a year ago. Capital expenditures were $19.3 million compared with $25.7 million a year ago. Non-GAAP measure of income from operations was $12.5 million compared with $5.4 million a year ago. Non-GAAP measure of net income was $7.9 million or $0.11 per basic and diluted share compared with $1.7 million or $0.02 per basic and diluted share a year ago. For the fiscal year ending December 31, 2015, the company now expects total revenue to be in the range of $544 million to $553 million; net loss in the range of $0.51 to $0.47 per share; non-GAAP net income in the range of $0.25 to $0.29 per share. Expected non-GAAP net income excludes approximately $39 million related to stock-based compensation expense, approximately $10 million related to the amortization of debt discount and transaction costs, and approximately $6 million related to the amortization of purchased intangible assets. The company continues to expect non-GAAP gross margin of approximately 53% for the full year. The company continues to target non-GAAP commercial gross margin of about 62% for 2015. The company expects total fourth quarter of 2015 revenue to be between $154 million and $160 million. The company expects total third quarter of 2015 revenue in the range of $125 million to $128 million. The company expects non-GAAP gross margin to improve to approximately 51% with relatively flat commercial gross margins and the lower mix of HBDC. The company targets a non-GAAP loss per share of $0.06 to $0.08 and a GAAP loss per share of $0.28 to $0.30.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPHD:US $56.00 USD +0.41

CPHD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DiaSorin SpA €42.42 EUR +0.62
Luminex Corp $17.31 USD +0.08
Meridian Bioscience Inc $18.40 USD +0.31
Quidel Corp $20.62 USD -0.09
Seegene Inc 53,600 KRW +1,600
View Industry Companies
 

Industry Analysis

CPHD

Industry Average

Valuation CPHD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.8x
Price/Book 10.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEPHEID INC, please visit www.cepheid.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.